We selected three genes that are targeted by FDA-approved inhibitors for treatment of leukemia: Bcl2 (inhibited by Venetoclax), Btk (Ibrutinib), and Kit (Imatinib) and plotted the calculated TPM values for each TT-seq replicate after DMSO and I-BRD9 treatment, connected by arrows (Fig. 2D; Supplementary Fig. S1G and S1H). This evidence concerns the gene BCL2 and leukemia.